Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28967900)

  • 1. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
    Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
    Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
    Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
    Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
    Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas.
    Brock SE; Rendon BE; Yaddanapudi K; Mitchell RA
    J Biol Chem; 2012 Nov; 287(45):37917-25. PubMed ID: 22988252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
    Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
    Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer.
    Guo C; Hao C; Shao R; Fang B; Correa AM; Hofstetter WL; Roth JA; Behrens C; Kalhor N; Wistuba II; Swisher SG; Pataer A
    Oncotarget; 2015 May; 6(13):11114-24. PubMed ID: 25798539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
    PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
    Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential.
    Goodwin JM; Svensson RU; Lou HJ; Winslow MM; Turk BE; Shaw RJ
    Mol Cell; 2014 Aug; 55(3):436-50. PubMed ID: 25042806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation.
    Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
    J Transl Med; 2011 Jun; 9():100. PubMed ID: 21718475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
    Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
    Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
    Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
    Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LKB1 mutation in large cell carcinoma of the lung.
    Zhong D; Guo L; de Aguirre I; Liu X; Lamb N; Sun SY; Gal AA; Vertino PM; Zhou W
    Lung Cancer; 2006 Sep; 53(3):285-94. PubMed ID: 16822578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.
    Malkoski SP; Haeger SM; Cleaver TG; Rodriguez KJ; Li H; Lu SL; Feser WJ; Barón AE; Merrick D; Lighthall JG; Ijichi H; Franklin W; Wang XJ
    Clin Cancer Res; 2012 Apr; 18(8):2173-83. PubMed ID: 22399565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.